Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 1402 | 7.05 |
09:34 ET | 166 | 7.03 |
09:36 ET | 154 | 6.96 |
09:39 ET | 710 | 6.98 |
09:41 ET | 100 | 7.045 |
09:45 ET | 556 | 7.07 |
09:48 ET | 1425 | 7.14 |
09:50 ET | 1782 | 7.1 |
09:52 ET | 1972 | 7.1161 |
09:54 ET | 100 | 7.07 |
09:57 ET | 1200 | 7.115 |
10:01 ET | 100 | 7.18 |
10:03 ET | 100 | 7.18 |
10:06 ET | 100 | 7.14 |
10:08 ET | 100 | 7.17 |
10:10 ET | 600 | 7.11 |
10:14 ET | 300 | 7.17 |
10:15 ET | 1400 | 7.14 |
10:28 ET | 200 | 7.13 |
10:48 ET | 1164 | 7.2 |
10:50 ET | 100 | 7.185 |
10:51 ET | 843 | 7.17 |
10:53 ET | 200 | 7.13 |
11:06 ET | 100 | 7.165 |
11:08 ET | 100 | 7.165 |
11:13 ET | 500 | 7.165 |
11:15 ET | 1100 | 7.199 |
11:18 ET | 1613 | 7.1702 |
11:20 ET | 100 | 7.17 |
11:24 ET | 200 | 7.13 |
11:27 ET | 100 | 7.1598 |
11:31 ET | 1500 | 7.14 |
11:36 ET | 100 | 7.12 |
11:40 ET | 623 | 7.1539 |
11:42 ET | 100 | 7.16 |
11:44 ET | 451 | 7.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 224.9M | -4.2x | --- |
Acrivon Therapeutics Inc | 224.9M | -2.7x | --- |
Kyverna Therapeutics Inc | 226.5M | 0.0x | --- |
Omeros Corp | 227.2M | -1.2x | --- |
Trevi Therapeutics Inc | 228.7M | -8.4x | --- |
Pyxis Oncology Inc | 221.1M | -2.9x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $224.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.